Axsome Therapeutics, Inc. (AXSM)

NASDAQ: AXSM · USD

$143

+1.02 (+0.7%)· Recorded snapshot

Market cap	7.5B
Revenue (ttm)	776.6M
Net income (ttm)	-191.6M
EPS (ttm)	-$3.76
Shares out	52.4M
Volume	631,074
Beta	0.85

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 776.6M
Net income (ttm): -191.6M
EPS (ttm): -$3.76
Market cap: 7.5B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Держать

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-245.1

P25 n/aP50 n/aP75 n/a

ROIC-38.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All AXSM indicators

Market & fundamental data

Available fields

211

Groups with data

Currency

USD

Showing 211 of 211 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001579428
Company name	Axsome Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	05464T104
Earnings date	2026-11-02
Earnings time	bmo
Employees	1,346
Employees change	500
Employees growth	59.1%
Enterprise value	$7.4B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2012
Industry	Biotechnology
IPO date	2015-11-19
Is primary listing	Yes
Is SPAC	No
ISIN number	US05464T1043
Last 10-K release date	2026-02-23
Last earnings date	2026-08-10
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$7.5B
Market cap category	Mid-Cap
Next earnings date	2026-11-02
Options	Yes
Price	$143.23
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	AXSM
U.S. state	New York
Website	https://www.axsome.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-2.63%
EV/Sales	9.57x
FCF / EV yield	-0.97%
FCF yield	-0.96%
Forward EV/Sales	6.25x
Forward P/S	6.33x
P/B ratio	89.28x
P/S ratio	9.69x
Price / tangible book value	221.97x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-23.55%
EBITDA margin	-22.27%
Gross margin	93.24%
Operating margin	-23.55%
Pretax margin	-24.61%
Profit margin	-24.68%
Profit per employee	$-142,380
Revenue per employee	$576,946
ROA	-16.31%
ROA (5Y)	-35.63%
ROCE	-60.75%
ROE	-245.1%
ROE (5Y)	-228.69%
ROIC	-38.2%
SBC / revenue	12.42%
Tax / revenue	0.07%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
Gross profit growth	59.89%
Gross profit growth (Q)	49.94%
Gross profit growth 3Y	62.99%
Net income growth years	1
Revenue growth	56.87%
Revenue growth (Q)	45.54%
Revenue growth (QoQ)	14.21%
Revenue growth 3Y	62.05%
Revenue growth quarters	9
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-700,000
Depreciation and amortization	$9.9M
EBIT	$-182.9M
EBITDA	$-172.9M
EPS	$-3.76
FCF per share	$-1.37
Financing cash flow	$88.8M
Free cash flow	$-72M
Free cash flow minus SBC	$-168.4M
Gross profit	$724M
Income taxes	$558,000
Investing cash flow	$-700,000
Net borrowing	$-3.1M
Net cash flow	$16.8M
Net income	$-191.6M
Operating cash flow minus SBC	$-167.7M
Operating income	$-182.9M
Revenue	$776.6M
Stock-based compensation	$96.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	5.09
Book value per share	$1.59
Debt / equity	2.7
Goodwill	$12M
Interest coverage	-14.2
Long-term assets	$104.9M
Long-term liabilities	$217.7M
Net cash (debt)	$95.2M
Net cash / market cap	1.26%
Net cash growth	11.02%
Net debt / equity	-1.14
Piotroski F-Score	3
Property, plant and equipment	$20M
Shareholders' equity	$83.3M
Tangible book value	$33.9M
Tangible book value per share	$0.65
Total assets	$761.4M
Total cash	$319.9M
Total debt	$224.7M
Total liabilities	$678.1M
WACC	8.81%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.11
Current assets	$656.6M
Current liabilities	$460.4M
Current ratio	1.43
Inventory turnover	1.87
Net working capital	$-47.6M
Quick ratio	1.3
Working capital	$196.1M
Working capital turnover	3.98

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-4.44%
Dividend yield	0%
Shareholder yield	-4.44%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	1,928.75%
10Y return CAGR	35.13%
10Y total return	1,928.75%
150-day SMA	$208.32
1D price change	0.72%
1M price change	-26.58%
1M total return	-26.58%
1W price change	-8.37%
1W total return	-8.37%
1Y price change	6.35%
1Y return CAGR	6.35%
1Y total return	6.35%
20-day SMA	$161.50
200-day SMA	$199.64
3M price change	-39.91%
3M total return	-39.91%
3Y price change	130.72%
3Y return CAGR	32.13%
3Y total return	130.72%
50-day SMA	$187.52
50-day SMA vs 200-day SMA	50under200
52-week high	$260.19
52-week high date	2026-06-18
52-week low	$123.50
52-week low date	2025-11-03
5Y price change	265.01%
5Y return CAGR	29.56%
5Y total return	265.01%
6M price change	-23.57%
6M total return	-23.57%
All-time high	$260.19
All-time high date	2026-06-18
All-time low	$1.94
All-time low date	2018-12-27
Average true range (ATR)	$6.55
Average volume	899.2K
Beta (1Y)	0.45
Beta (2Y)	0.86
Beta (5Y)	0.85
Change from 52-week high	-44.95%
Change from 52-week low	15.98%
Change from all-time high	-44.95%
Change from all-time low	7,282.99%
Change from open	1.58%
Day's gap	-0.84%
Dollar volume	$90.4M
High price	$144.14
Low price	$140.59
Monthly RSI	47.81
Open price	$141.00
Position in 52-week range	74.37%
Premarket change	-0.65%
Premarket close	$142.20
Premarket price	$141.28
Premarket volume	2K
Previous close	$142.20
Price vs 150-day SMA	-31.25%
Price vs 20-day SMA	-11.31%
Price vs 200-day SMA	-28.26%
Price vs 50-day SMA	-23.62%
Relative volume	0.71
RSI	22.06
Sharpe ratio	0.26
Sharpe ratio (3Y)	0.76
Sharpe ratio (5Y)	0.62
Sortino ratio	0.61
Sortino ratio (3Y)	1.41
Sortino ratio (5Y)	1.19
Volume	631.1K
Weekly RSI	31.01
YTD price change	-21.58%
YTD total return	-21.58%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	44.5M
Float percentage	84.88%
Shares change (QoQ)	1.17%
Shares change (YoY)	4.44%
Shares held by insiders	1.06%
Shares held by institutions	75.14%
Shares outstanding	52.4M
Short % of float	7%
Short % of shares	5.94%
Short ratio	4.8 days

Deeper analysis on AXSM

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this AXSM report

Is a complete AXSM research report available?

No complete published report is available for Axsome Therapeutics, Inc. (AXSM) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Axsome Therapeutics, Inc. (AXSM)

Price

Financial snapshot

Fair-value bridge

Latest news · AXSM

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AXSM indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on AXSM

Frequently asked questions